These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 8044193

  • 1. Dexfenfluramine reduces cardiovascular risk factors.
    Bremer JM, Scott RS, Lintott CJ.
    Int J Obes Relat Metab Disord; 1994 Apr; 18(4):199-205. PubMed ID: 8044193
    [Abstract] [Full Text] [Related]

  • 2. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT, Richman RM, Steinbeck KS, Caterson ID.
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [Abstract] [Full Text] [Related]

  • 3. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
    Swinburn BA, Carmichael HE, Wilson MR.
    Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1033-40. PubMed ID: 8923161
    [Abstract] [Full Text] [Related]

  • 4. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study.
    Lafreniere F, Lambert J, Rasio E, Serri O.
    Int J Obes Relat Metab Disord; 1993 Jan; 17(1):25-30. PubMed ID: 8383638
    [Abstract] [Full Text] [Related]

  • 5. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks.
    Drent ML, Zelissen PM, Koppeschaar HP, Nieuwenhuyzen Kruseman AC, Lutterman JA, van der Veen EA.
    Int J Obes Relat Metab Disord; 1995 May; 19(5):299-304. PubMed ID: 7647820
    [Abstract] [Full Text] [Related]

  • 6. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
    Pfohl M, Luft D, Blomberg I, Schmülling RM.
    Int J Obes Relat Metab Disord; 1994 Jun; 18(6):391-5. PubMed ID: 8081430
    [Abstract] [Full Text] [Related]

  • 7. The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity.
    Ditschuneit HH, Flechtner-Mors M, Adler G.
    J Cardiovasc Risk; 1996 Aug; 3(4):397-403. PubMed ID: 8946272
    [Abstract] [Full Text] [Related]

  • 8. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group.
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [Abstract] [Full Text] [Related]

  • 9. Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals.
    Holdaway IM, Wallace E, Westbrooke L, Gamble G.
    Int J Obes Relat Metab Disord; 1995 Oct; 19(10):749-51. PubMed ID: 8589769
    [Abstract] [Full Text] [Related]

  • 10. Consumption of a controlled low-fat diet containing olestra for 9 months improves health risk factors in conjunction with weight loss in obese men: the Ole' Study.
    Lovejoy JC, Bray GA, Lefevre M, Smith SR, Most MM, Denkins YM, Volaufova J, Rood JC, Eldridge AL, Peters JC, Ole' Study.
    Int J Obes Relat Metab Disord; 2003 Oct; 27(10):1242-9. PubMed ID: 14513073
    [Abstract] [Full Text] [Related]

  • 11. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC, Ko GT, Tsang LW, Yeung VT, Chan JC, Cockram CS.
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [Abstract] [Full Text] [Related]

  • 12. A double-blind, randomized, controlled trial of the effects of two eggs per day in moderately hypercholesterolemic and combined hyperlipidemic subjects taught the NCEP step I diet.
    Knopp RH, Retzlaff BM, Walden CE, Dowdy AA, Tsunehara CH, Austin MA, Nguyen T.
    J Am Coll Nutr; 1997 Dec; 16(6):551-61. PubMed ID: 9430083
    [Abstract] [Full Text] [Related]

  • 13. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
    Geyer G, Haidinger G, Francesconi M, Langmayr N, Prager R, Schoberberger R, Toplak H, von Kalckreuth G, Kunze M.
    Acta Med Austriaca; 1995 Dec; 22(5):95-101; 104-9. PubMed ID: 8651045
    [Abstract] [Full Text] [Related]

  • 14. High protein diets decrease total and abdominal fat and improve CVD risk profile in overweight and obese men and women with elevated triacylglycerol.
    Clifton PM, Bastiaans K, Keogh JB.
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):548-54. PubMed ID: 19179060
    [Abstract] [Full Text] [Related]

  • 15. Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women: a randomized, double-blind study.
    Aubertin-Leheudre M, Lord C, Khalil A, Dionne IJ.
    Menopause; 2007 Oct; 14(4):624-9. PubMed ID: 17290158
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term effects of a high-protein, low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects.
    Brinkworth GD, Noakes M, Keogh JB, Luscombe ND, Wittert GA, Clifton PM.
    Int J Obes Relat Metab Disord; 2004 May; 28(5):661-70. PubMed ID: 15007396
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The metabolic effects of preferential reduction of visceral adipose tissue in abdominally obese men.
    Marks SJ, Chin S, Strauss BJ.
    Int J Obes Relat Metab Disord; 1998 Sep; 22(9):893-8. PubMed ID: 9756248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.